iCAD have long been among the frontrunners in the breast imaging AI market. Although breast imaging is one of the longest established use cases for medical imaging AI, the vendor has, in the past, still performed strongly compared to its peers.
This strength continued during 2020 and 2021 when the Covid-19 pandemic was most prevalent, which, in many cases, caused breast screening programmes to be paused. Despite such a setback the vendor was able to maintain, if not increase revenues.
However, such a run has ended, with the vendor’s latest results showing a decline of more than 20% in its detection product revenue. Of more concern, this, combined with results from its other segments, means that overall, in 2022, iCAD’s expenses were 21% higher than its revenues.
Radnet has announced that it is using AI to offer patients more detailed breast screening examinations as part of its Enhanced Breast Cancer Detection (EBCD) service. The new service will enable women attending their annual breast screening examinations to, for an additional fee, receive additional services which include the use of AI tools to assess a woman’s lifetime breast cancer risk.
EBCD utilises the Saige-Dx, a US-FDA cleared mammography diagnostic aid software from DeepHealth (a RadNet acquired company), adds an additional review applied to any suspicious
